A team of Indian scientists from the Agharkar Research Institute (ARI) has developed a novel approach to combat breast cancer by using nanoparticles to silence genes that keep cancer cells alive. Breast cancer cells are known for their ability to resist treatment, carrying proteins that act as a "do not die" switch, promoting tumor growth and frustrating medical interventions.
How the Nanoparticle Works
The nanoparticle, thousands of times smaller than a human hair, is engineered to carry a molecular message into the heart of a cancer cell. Once inside, it silences the genes responsible for the tumor's survival, effectively cutting off the instructions the cell needs to thrive. This method is less like a bomb and more like precise interference, stopping the cancer cell from receiving survival signals.
Targeting Cancer Cells Precisely
What sets this approach apart is its ability to specifically target cancer cells. Breast cancer cells are coated with a protein called MUC1, which is largely absent in healthy cells. The scientists fitted their nanoparticle with a biological key that recognizes MUC1, allowing it to dock onto cancer cells while ignoring healthy tissue. This selectivity is crucial, as conventional chemotherapy often attacks the entire body to reach the tumor, causing severe side effects.
Additionally, the nanoparticle releases its payload only when inside the cancer cell, triggered by a chemical present in tumors. This ensures that the treatment is activated only in the right environment.
Laboratory Results
In laboratory tests, the approach proved effective. According to the Department of Science and Technology (DST), of which ARI is an autonomous institute, tumors in mice shrank significantly, cancer cells died, and surrounding healthy tissue showed little damage. This distinguishes the treatment from many existing therapies.
The research, led by Niladri Haldar, Rajkumar Samanta, Surajit Patra, Devyani Sengar, Sachin Jadhav, and Virendra Gajbhiye, was published in the journal Advanced Healthcare Materials. While still at an early stage, the findings offer a blueprint for a new kind of cancer medicine that targets the disease at its genetic roots rather than using a blanket approach.
For millions of women diagnosed with breast cancer each year, such precision cannot come soon enough. The scientists emphasize that there is a long road between promising results in mice and a drug that doctors can prescribe, but the potential is significant.
